Introduction
============

Usher syndrome (USH) is a genetically and clinically heterogeneous autosomal recessive disorder that associates sensorineural hearing loss, retinitis pigmentosa (RP), and in some cases vestibular dysfunction. It accounts for over 50% of cases of hereditary forms combining deafness and blindness and has an estimated prevalence of 3 to 6.2 per 100,000 \[[@r1]\].

USH is divided into three clinical subtypes: Usher type 1(USH1), type 2 (USH2), and type 3 (USH3) \[[@r2]\]. USH1 displays severe--profound congenital deafness, absent vestibular function, and prepubertal onset of RP; in USH2 hearing loss is congenital, moderate to severe, with normal vestibular function, and pre- or postpubertal onset of RP; and in USH3, hearing loss may be pre- or postlingual but is progressive in course, with normal or abnormal vestibular function and often postpubertal onset of RP. Although this classification is generally deemed adequate, atypical clinical types have also been described \[[@r3]\].

To date, ten genes have been associated with this disease. For USH1, six genes have been identified: *MYO7A* (USH1B), *USH1C* (USH1C), *CDH23* (USH1D), *PCDH15* (USH1F), *USH1G* (USH1G) \[[@r4]\], and *CIB2* (USH1J) \[[@r5]\]. Three genes have been found to cause USH2: *USH2A* (USH2A), *GPR98* (USH2C), and *DFNB31* (USH2D). Only the *CLRN1* gene has been described for USH3. Most of these genes are also responsible for nonsyndromic hearing loss or isolated RP \[[@r4]\]. In addition to these ten genes, three other genes have been associated with USH. *PDZD7* was proposed to contribute to digenic inheritance with *GPR98* and also to have a role as a retinal disease modifier in *USH2A* patients \[[@r6]\]. Recently, a novel missense variant in *HARS* was identified in homozygosis in two patients with a phenotype compatible with USH3 \[[@r7]\]. Thus, this gene was proposed to be a novel gene causative for USH3 \[[@r4]\]. More recently, the *CEP250* gene has been associated with atypical Usher syndrome \[[@r8]\]. Usher syndrome is included in a group of hereditary pathologies associated with defects in ciliary function known as ciliopathies \[[@r9]\] most USH1 and USH2 proteins are integrated in a protein network known as the "Usher-interactome" \[[@r10]\]. The central core of the interactome is formed by PDZD7, harmonin (*USH1C*), and whirlin (*DFNB31*), and the microtubule-associated protein SANS (*USH1G*). The remaining USH proteins are attached to this core \[[@r11]\]. This interacting network is mainly localized at the stereocilia or hair bundle of the inner ear hair cells and at the periciliary areas of the photoreceptors \[[@r12],[@r13]\]. In the inner ear, Usher proteins play an essential role for correct development and cohesion of the hair bundle of hair cells in the cochlea and vestibular organ \[[@r14]-[@r18]\]. In the retina, the Usher protein network provides mechanical support to the membrane junction between the inner segment and the connecting cilium, participating in the control of vesicle docking and cargo handover in the periciliary ridge \[[@r19],[@r20]\].

USH2 accounts for well over one-half of all Usher cases. Mutations in the *USH2A* gene are responsible for the majority of USH2 cases and are also responsible for atypical Usher syndrome \[[@r21],[@r22]\] and recessive nonsyndromic RP \[[@r23],[@r24]\]. Two main isoforms of the *USH2A* gene, the short isoform_a and the long isoform_b, have been described. The short isoform_a, which is reported to be 5 kb (exons 2--21; 1,547 amino acids \[aa\]), encodes a protein of 170 kDa \[[@r25],[@r26]\]; the long isoform_b, which expands the whole length of the coding sequence to 15 kb (exons 2--72; 5,202 aa), encodes a large protein of 600 kDa \[[@r27]\]. The mutational spectrum of *USH2A* is extensive. Over 350 different point mutations, including nonsense, frameshift, missense, and splicing mutations ([USH2A](http://www.lovd.nl/USH2A)), have been identified by numerous mutation screenings.

Conventional *USH2A* mutation screenings have been performed by PCR amplification of coding exons followed by Sanger sequencing \[[@r28]-[@r30]\]. However, large duplications and large heterozygous deletions are not detectable if the breakpoints are located outside the amplified region. Recently, the multiplex ligation-dependent probe amplification (MLPA) and oligonucleotide array-based comparative genomic hybridization (aCGH) techniques have facilitated the detection of total and partial gene deletions and duplications that may escape conventional PCR-based screening methods \[[@r31],[@r32]\]. Using these technologies, Steele-Stallard et al. \[[@r33]\] characterized five deletions and one duplication in heterozygosis in the *USH2A* gene in patients who had missing mutations (mono-allelic *USH2A*) or no mutations following Sanger sequencing.

Missing mutations can also lie in the promoter or deep intronic zones, which are usually not analyzed in conventional mutation screenings. In this regard, Vaché et al. \[[@r34]\] identified a deep intronic mutation (c.7595--2144A\>G) after sequencing mRNA transcripts obtained from nasal epithelial cells of USH2 patients. Taking this into account, we screened our USH2 cohort of patients with unidentified mutations for c.7595--2144A\>G and found it in five heterozygote and one homozygote cases.

In the present study, we used the MLPA technique to screen our cohort of USH2 patients for large deletions and duplications affecting the *USH2A* gene. Subsequently, we applied a customized oligonucleotide aCGH assay to confirm the presence of rearrangements and accurately determine the location of their breakpoints.

Methods
=======

Patients
--------

Thirteen nonsyndromic recessive RP patients \[[@r35]\] and 88 USH cases \[[@r30],[@r34]\] were previously screened for point mutations in *USH2A* by Sanger sequencing \[[@r17],[@r21],[@r22]\]. In 42 of the patients (31 USH and 11 RP), point mutations in both *USH2A* alleles were identified. In a later study, seven USH patients were found to carry mutations in *DFNB31* \[[@r36]\]. After these studies, only 39 out of the remaining 52 samples were useful for MLPA analysis to search for large deletions/duplications in the *USH2A* gene. A DNA sample of one USH patient carrying a homozygous *USH2A* deletion of exons 9--14 inferred from consistent PCR nonamplification \[[@r37]\] was included as a positive control ([Figure 1](#f1){ref-type="fig"}).

![Diagram explaining the selection of patients for this study. Initially, 101 non-related patients, 13 diagnosed with retinitis pigmentosa (RP) and 88 diagnosed with Usher syndrome (USH) were screened for point mutations in *USH2A* by Sanger sequencing. Point mutations in both *USH2A* alleles were identified in 42 of them. Later one, seven USH patients were found to carry mutations in *DFNB31*. After all these previous studies, 13 USH DNA samples were degraded and only 39 samples were useful to perform the MLPA analysis to search for large deletions/duplications in the *USH2A* gene. Finally, an additional DNA sample from a patient carrying a homozygous *USH2A* deletion involving exons 9-14 was included in the study as a positive control for the MLPA analysis.](mv-v20-1398-f1){#f1}

Thus, 40 unrelated patients (38 USH and two RP) were included in this study. Twelve of them (ten USH and two RP) carried one heterozygous *USH2A* point mutation, and one USH patient carried a suspected homozygous *USH2A* deletion.

Of the USH patients, 24 were classified as USH2 on the basis of ophthalmic studies that included visual acuity, visual field, fundus ophthalmoscopy, electroretinography, pure-tone and speech audiometry, and vestibular evaluation. Seven patients were classified as atypical USH, and detailed clinical data could not be obtained for another seven patients. For each patient, samples from parents as well as from siblings were obtained, when possible.

This research adhered to the tenets of the Declaration of Helsinki. The study was approved by the Hospital La Fe Ethics Committee, and consent for genetic testing was obtained from adult probands or the parents of the minors.

MLPA analysis
-------------

MLPA was used to determine the copy number of all *USH2A* exons (72) in two single multiplex PCR-based reactions. P361 and P362 SALSA MLPA kits (probemixes) were used (MRC Holland, Amsterdam, the Netherlands). P361 probemix contained 36 adjacent paired probes for odd exons, and P362 probemix contained another 36 paired probes for even exons. The MLPA analysis used 50 ng of DNA, diluted in 5 μl of Tris/EDTA buffer. During PCR, adjacent MLPA probes correctly ligated after hybridization to the sample DNA were amplified, and each MLPA reaction resulted in a set of PCR amplicons. One microliter of each reaction product was separated on POP-7 polymer by capillary electrophoresis with a DNA analyzer (model 3500XL; Applied Biosystems, Inc. \[ABI\], Foster City, CA). Freely available software provided by MRC Holland was used to analyze the MLPA data ([Coffalyser](http://www.mlpa.com); MRC Holland). Using this program, data generated was first normalized intra-sample by dividing the peak area of each probe's amplification product by the total area. Second, inter-sample normalization was achieved by dividing the intra-normalized probe ratio in a sample by the average intra-normalized probe ratio of the reference sample. A probe dosage quotient value of 1±0.3 was considered normal; less than 0.7 was considered a deletion and greater than 1.3 a duplication.

Oligonucleotide aCGH
--------------------

A custom aCGH chip (12×135 k) was used to compare control DNA (or reference sample) to DNA from the patient (test sample) that was labeled with two different dyes. Both DNAs were co-hybridized onto the chip containing 77,366 immobilized probes covering the genes *MYO7A*, *CDH23*, *PCDH15*, *USH1C*, *USH1G*, *USH2A*, *GPR98*, *DFNB31*, *PDZD7,* and *USH3A* and 10,000 nucleotides of 5′ and 3′ untranslated regions (UTRs) \[[@r32]\]. The average probe length was 60 bases, and the spacing between starts of probes covering exons and introns was 35 bp. Hybridization was performed in a high-resolution microarray platform (Roche NimbleGen, Inc., Basel, Switzerland). The slides were scanned using InnoScan900A (Inopsys, Toulouse, France) and analyzed using Deva1.2.1 software (Roche NimbleGen, Inc.). The signal intensity ratio between a test sample and a reference sample was normalized and converted to a log2 ratio to identify copy number changes, which were indicated by a deviation from the normal log2 ratio of zero. The predicted breakpoint location was defined by the positions of the last and first probes with the normal unaveraged value of the log2 ratio upstream and downstream from the corresponding aberration.

Identification of breakpoints
-----------------------------

Specific primer pairs were designed to amplify patients' genomic DNA regions where deletion breakpoints were indicated by the aCGH analysis (see [Table 1](#t1){ref-type="table"}). The primers were located 400--1,000 nt upstream and downstream of the last deleted probe in each deletion end. The PCR products were directly sequenced. The genomic *USH2A* reference sequence for deletions nomenclature using [Mutalyzer 2.0](https://mutalyzer.nl/). beta-29 program was NG_009497.1.

###### Primers used to amplify and sequence breakpoint junctions of deletions characterized in the present study.

  Patient   Primer      Sequence 5′-3′
  --------- ----------- ------------------------
  RP-1622   IVS13-F     TACCAGAGACTATGTTGGTG
            IVS14-R     GCTTCTCAGGGATAGGAGC
  RP-838    IVS4-F1     CGAAACTGTCAATAATTCTGG
            IVS13--2R   GAGCTAATATTGGCTGACAG
  RP-1638   IVS4-F      GTATCAGGATGATGCTGGCC
            IVS9-R      GCATATTTACGGGCATGGTAG
  RP-1678   IVS21--1D   TAACCACAATCCACTAGCTTG
            IVS29--3R   AATCATCTGGAGATGTGTTCAG

Results
=======

The present study led to the detection of six different partial *USH2A* gene deletions in six out of the 40 unrelated cases studied. Three of these deletions were homozygotes, and the remaining three were compound heterozygotes, having a previously *USH2A* point mutation identified. In five cases patients displayed Usher syndrome, and the remaining patient presented with nonsyndromic RP (summarized results in [Table 2](#t2){ref-type="table"}).

###### Summary of *USH2A* deletions identified in our cohort of patients.

  Family      Patient           Allele 1                     Allele 2         Daignosis   References
  ----------- ----------------- ---------------------------- ---------------- ----------- --------------------------------------------
  FRP-429§    RP-1696/RP-1697   del ex 9--14\*               del ex 9--14\*   USH2        \*Bernal et al. (2005) \[[@r37]\]
  FRP-404     RP-1622           del ex 14                    del ex 14        USH2        
  FRP-298     RP-838            del ex 5--13                 del ex 5--13     USH2        
  FRP-323     RP-1397           c.8167C\>T/p.R2723X          del ex 1--4      USH2        
  FRP-413     RP-1637/RP-1638   c.5540dupA/p.N1848EfsX20\*   del ex 5--9      USH2        \*García-García et al. (2011) \[[@r30]\]
  FRP-423\#   RP-1678/RP-1679   c.2276G\>T/p.C759F\*         del ex 22--29    ARRP        \*Avila-Fernandez et al. (2010) \[[@r35]\]

§In the work by Bernal et al., (2005) \[[@r37]\] this family corresponds to Ush-148. \#In the paper by Avila-Fernandez et al. (2010) \[[@r35]\] this family corresponds to RP-1016. Novel deletions identified in this report are in bold.

MLPA and segregation analysis
-----------------------------

### Homozygous cases

In patients RP-1696 and RP-1697, which belong to the same family (FRP-429), a homozygous deletion involving exons 9--14 had already been inferred from consistent PCR nonamplification (family Ush-148 in \[[@r37]\]). Thus, these patients were used as positive controls.

Patient RP-1622 showed no point mutations after *USH2A* screening by direct sequencing. All polymorphisms detected were in homozygosis, and exon 14 was impossible to amplify, strongly suggesting the existence of one deletion in this region.

In patient RP-838, amplification of exons 5--13 failed, suggesting the existence of a rearrangement within this area. MLPA analysis detected homozygous deletions in three cases: a deletion of exons 9--14 in patients RP-1696 and RP-1697 (FRP-429); a deletion of exon 14 in patient RP-1622 (FRP-404), and a deletion involving exons 5--13 in patient RP-838 (FRP-298). Three deletions co-segregated with the disease in three families. All three referred consanguinity ([Figure 2A-C](#f2){ref-type="fig"}).

![Family pedigrees showing segregation analysis of *USH2A* deletions identified in this study. **A**: Segregation analysis of the *USH2A* deletion involving exons 9-14 (del ex 9-14) performed in available DNA samples from family FRP-429. **B**: Segregation analysis of exon 14 *USH2A* deletion (del ex 14) performed in available DNA samples from family FRP-404. **C**: Segregation analysis of deletion involving exons 5-13 (del ex 5-13) of *USH2A* in family FRP-298. **D**: Segregation analysis of the *USH2A* mutations p.R2723X and deletion of exons 1-4 (del ex 1-4), performed in available samples from family FRP-323. **E**: Segregation analysis of the *USH2A* mutations p.5540dupA and deletion of exons 5-9 (del ex 5-9), performed in both affected patients from family FRP-413. **F**: Segregation analysis of the *USH2A* mutations p.C759F and deletion of exons 22-29 (del ex 22-29), performed in available DNA samples from family FRP-423.](mv-v20-1398-f2){#f2}

In patients RP-1696 and RP-1697 (homozygous for exons 9--14 deletion), RP started when the patients were around 30-years old. At the age of 50, electroretinogram (ERG) responses ceased in both patients, who presented typical RP eye-fundus examination results. Vestibular function was normal in both cases. Hearing loss was prelingual and severe. In patient RP-1696, the loss of hearing was progressive, whereas in patient RP-1697, it was nonprogressive \[[@r37]\].

Patient RP-1622 (homozygous for exon 14 deletion) displayed typical USH2 clinical manifestations: RP started when the patient was around 23-years old; hearing loss was congenital, stable, and moderate to severe. Vestibular function in this patient was normal.

Patient RP-808 (homozygous for exons 5--13 deletion) was referred first with RP symptoms at the age of 12 but was diagnosed with USH2 at the age of 14. At that time, he presented hearing loss, ERG responses ceased, visual acuity was 0.08, and visual field showed a concentric reduction, preserving only 5 central degrees.

Heterozygous cases
------------------

A heterozygous deletion affecting exons 1--4 was detected in patient RP-1397. This patient was already found to carry the mutation c.8167C\>T/p.Arg2723\* (unpublished results). Segregation analysis showed that the deletion was inherited from the healthy mother ([Figure 2D](#f2){ref-type="fig"}). Sensorineural hearing loss was first suspected in this patient at the age of 7. Results from audiograms performed when the patient was 19, 24, 30, and 35 years showed a stable moderate--severe hearing loss, which was accentuated at higher frequencies. RP started when the patient was around 30-years old. Ophthalmologic evaluations at the age of 39 showed abolished ERG responses, visual acuity was 0.6, and visual field was tubular with islets. An eye fundus examination ([Figure 3](#f3){ref-type="fig"}) showed bone spicule deposits, attenuation of vessels, and a waxy pallor of the optic nerve head. The macula of this patient was normal.

![Eye fundus images obtained after examination of patient RP-1397 show bone spicule deposits, attenuation of vessels and waxy pallor of the optic nerve head in both eyes.](mv-v20-1398-f3){#f3}

In patient RP-1638, MLPA analysis indicated the presence of a deletion involving exons 5--9. This patient was previously found to carry the c.5540dupA mutation \[[@r30]\]. His affected brother (RP-1637) also carried both mutations ([Figure 2E](#f2){ref-type="fig"}). These patients were referred to our laboratory as USH2. Unfortunately, it has not been possible to obtain more detailed clinical data.

Finally, a heterozygous deletion of exons 22--29 was detected in a patient (RP-1678) who carried the c.2276G\>T/p.Cys759Phe mutation \[[@r35]\]. Segregation analysis in this family showed that the affected brother (RP-1679) carried both mutations, whereas the healthy brother only carried the partial *USH2A* deletion ([Figure 2F](#f2){ref-type="fig"}). Detailed clinical data could not be obtained for RP-1678. In his affected brother, RP-1679, RP was diagnosed when he was 35-years old. At the age of 38, ERG responses were abolished, visual acuity was good (1), but visual field was concentrically reduced to only 10 central degrees. Eye fundus examination of this patient revealed bone spicule deposits in the peripheral retina, attenuation of vessels, and a waxy pallor of the optic nerve head. Currently (48-years old), this patient has noted a slight degree of hearing loss. Unfortunately, it has not been possible to confirm this by audiological evaluation.

Oligonucleotide aCGH analysis and identification of breakpoint positions
------------------------------------------------------------------------

An aCGH analysis was performed to confirm the deletions detected by MLPA and to precisely define the breakpoint positions. Unfortunately, the amount and quality of the DNA from patients RP-1696/RP-1697 DNA was not sufficient to perform the aCGH analysis.

RP-1622
-------

The results from aCGH analysis indicated that the deletion expanded from approximately chromosome 1 positions 216,404,500 to 216,409,000. A specific primer pair ([Table 1](#t1){ref-type="table"}) was designed to amplify and sequence this region. Sequencing of the PCR product obtained using these primers identified the exact breakpoints from nucleotides g.192,143 (intron 13) to g.197,160 (intron 14); ([Figure 4A](#f4){ref-type="fig"}), confirming the presence of a deletion of over 5 kb (c.2810--4121_2993+718del). The deletion of exon 14 is expected to generate a premature stop codon, translated into a truncated protein: p.Gly937Aspfs\*13.

![Breakpoint junctions of *USH2A* deletions characterized by PCR amplification and sequencing. **A**: Exact breakpoints of deletion involving exon 14 of *USH2A* in patient RP-1622. **B**: Exact breakpoints of deletion involving exons 5-13 of *USH2A* in patient RP-838. **C**: Exact breakpoints of deletion involving exons 5-9 of *USH2A* in patient RP-1638. **D**: Exact breakpoints of deletion involving exons 22-29 of *USH2A* in patient RP-1678. IVS: Intervening sequence.](mv-v20-1398-f4){#f4}

RP-838
------

aCGH analysis showed the presence of a deletion expanding around chromosome 1 positions 216,420,000 to 216,520,000. After PCR amplification and sequencing using a specific primer pair ([Table 1](#t1){ref-type="table"}), exact breakpoint positions were identified, showing a deletion expanding from g.82,673 (intron 4) to g.182,184 (intron 13); ([Figure 4B](#f4){ref-type="fig"}). This deletion (c.785--18070_2809+372del) is expected to be in-frame, resulting in a protein lacking 675 aa (p.Leu263_Gly937del).

RP-1397
-------

Results of aCGH analysis from this patient indicated the existence of a deletion expanding from approximately chromosome 1 positions 216,511,000 to 216,606,000. Three different pairs of primers were designed to amplify the breakpoint deletions in this patient. Unfortunately, no PCR products were obtained using RP-1397 and RP-1395 DNAs.

RP-1638
-------

In this case, a deletion was found around chromosome 1 positions 259,216,460,000 to 216,510,000. Specific PCR amplification and sequencing showed that the deletion affected nucleotides g.79,628 (intron 4) to g.135,435 (intron 9) spanning 55.8 kb (c.784+16184_1645--592del; [Figure 4C](#f4){ref-type="fig"}). The loss of exons 5 to 9 is expected to generate a truncated protein p.(Gly262Valfs\*2).

RP-1678
-------

aCGH results indicated a deletion spanning chromosome 1 positions 216,246,000 to 216,309,000. Sequencing after PCR amplification showed a deletion of 62.7 kb from g.292,921 (intron 21) to g.355,667 (intron 29), ([Figure 4D](#f4){ref-type="fig"}). This deletion (c.4628--38263_5857+159del) would produce the loss of the in-frame exons 22--29; generating a protein lacking amino acids 1,543--1,952 (p.Gly1543_Ala1952del).

Discussion
==========

In this study we detected six large deletions in six unrelated patients affecting the *USH2A* gene (five of them not previously described), using the MLPA technique. In three cases, the deletions were detected to be in a homozygous state. In the remaining three probands, deletions were found to be *in trans* with a *USH2A* point mutation previously identified.

From an initial cohort of 101 patients, a *USH2A* mutation screening by Sanger sequencing allowed the identification of mutations in both *USH2A* alleles responsible for the disease in 42 cases \[[@r30],[@r34],[@r35]\]. The present study, searching for large rearrangements, allowed the identification of both *USH2A* mutated alleles in six additional cases (three heterozygous and three homozygous). It is difficult to estimate the contribution of large deletions to the total mutational spectrum of *USH2A* based on our studies since our data are biased (see [Figure 1](#f1){ref-type="fig"}). However, if we used these data (all patients with both *USH2A* mutated alleles detected: 48 patients, 96 alleles) as an approximation of the real population, we might predict that large deletions would represent 9.4% (nine out of 96) of all *USH2A* mutations.

Interestingly, one of the cases with a novel *USH2A* deletion identified in this study was a nonsyndromic RP patient. RP-1678 was found to carry a heterozygous in-frame deletion of exons 22--29 *in trans* with the c.2276G\>T/p.Cys759Phe point mutation. As expected, the affected brother (RP-1679) also carried both mutations. Both patients were initially diagnosed with nonsyndromic RP, but RP-1679 (now 48-years old) presents with a slight degree of hearing loss. Heterogeneous phenotypes have been correlated with the p.Cys759Phe mutation in this and other previous studies ([USH2A](http://www.lovd.nl/USH2A)). Thus, whereas those patients who are compound heterozygous for p.Cys759Phe and another *USH2A* mutation can display RP \[[@r23],[@r24],[@r35],[@r38],[@r39]\], atypical USH \[[@r21],[@r22]\], or USH2 \[[@r25]-[@r30]\], patients homozygous for the p.Cys759Phe mutation are correlated with nonsyndromic RP \[[@r22],[@r23],[@r35],[@r38]-[@r40]\].

MLPA is the most rapid and cost-efficient method to search for large deletions/duplications involving the *USH2A* gene. It allows determination of the copy number of all *USH2A* coding exons (72) in only two multiplex PCR-based reactions. Nevertheless, it is recommended that the presence of rearrangements detected by MLPA be confirmed by other techniques, like aCGH analysis, real-time quantitative PCR, or reverse-transcription (RT)--PCR, on RNA obtained from nasal epithelial cells \[[@r34]\], fibroblasts \[[@r33]\], or hair roots \[[@r41]\]. In the present work, a customized aCGH, including intron *USH2A* gene sequences, was applied to confirm the presence of deletions detected by MLPA and to accurately determine their breakpoint positions. Unfortunately, breakpoints could not be successfully determined in two cases. In family FRP-429, the amount and quality of the DNA samples were not sufficient to perform the aCGH analysis.

In family FRP-323, aCGH was successfully performed, pointing out the location of breakpoints around chromosone 1 positions: 216,511,000 (5′ UTR region) and 216,606,000 (intron 4). This result was in agreement with MLPA analysis that showed a deletion involving exons 1--4. However, the breakpoints in that DNA region could not be amplified by PCR, suggesting that the rearrangement may be more complex than suspected. In this regard it is worth noting that Le Guédard et al. \[[@r42]\] also failed to determine the exact breakpoint junctions for two large deletions affecting the *PCDH15* gene. These results together with ours point to the existence of large complex rearrangements involving USH genes and highlight the difficulty in characterizing them.

To date, only 12 different large deletions within the *USH2A* gene have been reported ([USH2A](http://www.lovd.nl/USH2A)). None of these coincide with the five novel deletions detected in our patients except the deletion involving exon 14. Recently, Glöckle et al. \[[@r40]\] identified a deletion also involving this exon; but exact breakpoints have not been described. Consequently, we are unable to compare, and therefore know, if this deletion is the same as that found in our patient RP-1622.

It has been proven by this work and several other studies that an exhaustive molecular screening of USH genes must include approaches (such as MLPA or aCGH analysis) other than sequencing. These screenings based upon conventional techniques are time intensive and expensive and therefore are thought to be replaced by next-generation sequencing (NGS) approaches. Whole exome capture and targeted USH exome sequencing have specifically been applied for Usher syndrome \[[@r43]-[@r45]\]. These studies confirm the urgency to improve base calling and alignment software to accurately identify point mutations and specific bioinformatics' tools to detect copy number variations (CNVs) using NGS methodologies. The detection of CNVs (large deletions and duplications) in concert with other variants in a single experiment will help to reduce total cost, time, and complexity and will allow researchers to gain a broader insight into disease from a limited amount of DNA sample. Deep intronic mutations (such as c.7595--2144A\>G) recently identified in *USH2A* by mRNA studies \[[@r34]\] may be involved in some cases. Future approaches of targeted re-sequencing of USH genes, including sequences from noncoding regions (UTRs and introns), are needed to further identify this kind of mutation.

The development of efficient and cost-effective strategies to identify disease-causing mutations is mandatory. Determination of the underlying genetic defect in a patient is a prerequisite for gene or mutation-specific therapy. In this sense, preliminary results in gene therapeutic approaches for Usher syndrome \[[@r46]-[@r48]\] are promising.
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